The new oral anticoagulants

Netherlands Heart Journal

Volumn 18, Issue 6, 2010, Pages 314-318

  Verheugt, F W A ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

Administration; Anticoagulants; Atrial fibrillation; Drug discovery; Oral; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; COUMARIN DERIVATIVE; DABIGATRAN; EDOXABAN; HEMATOLOGIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LUNG EMBOLISM; MONOTHERAPY; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 77955953698     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03091782     Document Type: Review

References (23)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke. The Framingham study. Arch Intern Med. 1987;147:1561-4.
2. Kopecky SL, Gersh BJ, McGoon MD, et al. The natural history of lone atrial fibrillation: A population-based study over three decades. N Engl J Med. 1987;317:669-74.
3. Lip GY, Hart RG, Conway DS. Antithrombotic therapy for atrial fibrillation.BMJ. 2002;325:1022-5.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
5. De Caterina R, Husted S, Wallentin, L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007;28:880-913.
6. Van Es RF, Jonker JJC, Verheugt FWA, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002:360:109-13.
7. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-74.
8. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72.
9. CURE Investigators. Effect of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
10. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17.
11. ACTIVE Investigators. Randomized controlled trial of clopidogrel plus aspirin versus oral anticoagulation in patients with atrial fibrillation: The Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE). Lancet. 2006;367:1903-12.
12. Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet. 2006;367:1877-8.
13. Hellemons BSP, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:175-8.
14. Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet. 2007;370:460-1.
15. Mant J, Hobbs R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
16. SPORTIF-III Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (SPORTIF-III): randomised controlled trial. Lancet. 2003;362:1691-8.
17. Albers GW, Diener HC, Frison L, et al Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-8.
18. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation. 2007;116:180-7.
19. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75.
20. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a doubleblind, randomized controlled trial. Lancet. 2008;372:31-9.
21. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86.
22. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD-4). Lancet. 2009;373:1673-80.
23. Verheugt FWA. Good old warfarin for stroke prevention in atrial fibrillation. Lancet. 2006;367:1877-8.